瓮福(集团)有限责任公司 2020 年度、2021 年度、2022 年度及 2023 年 1-5 月审计报告 天 职 业 字 [2023]43940 号 日 录 ———1 报 告 -- 财务报表 -22 财务报表附注 -------- "。 审计报告 天职业字[2023]43940 号 瓮福（集团）有限责任公司: 一、审计意见 我们审计了瓮福(集团)有限责任公司(以下简称贫福公司)财务报表,包括 2023 年 1-5 月、2022年 12 月 31 日、2021年 12 月 31 日、2020 年 12 月 31 目的合并及母公司资产 负债表,2023年 1-5 月、2022年度、2021 年度、2020 年度的合并及母公司利润表、合并及 母公司现金流量表、合并及母公司所有者权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 会福公司 2023 年 1-5 月、2022 年 12 月 31 日、2021 年 12 月 31 日、2020 年 12 月 31 日的 合并及母公司财务状况以及 2023 年 1-5 月、2022 年度、2021 年度、20 ...

华创证券有限责任公司 关于 贵州中毅达股份有限公司 发行股份购买资产并募集配套资金 暨关联交易之 独立财务顾问报告 （修订稿） 二〇二三年八月 2-1-1 独立财务顾问声明与承诺 华创证券有限责任公司（以下简称"独立财务顾问"）接受贵州中毅达股份 有限公司（以下简称"上市公司"）的委托，担任其发行股份购买资产并募集配 套资金暨关联交易的独立财务顾问，并出具独立财务顾问报告。 本独立财务顾问报告是依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管 理办法》《公开发行证券的公司信息披露内容与格式准则第 26 号——上市公司 重大资产重组申请文件》《关于规范上市公司重大资产重组若干问题的规定》等 相关法律法规的规定，按照证券行业公认的业务标准、道德规范和诚实信用、 勤勉尽责精神，经审慎尽职调查后出具的，旨在对本次交易作出独立、客观和 公正的评价，以供上市公司全体股东及有关方面参考。 本独立财务顾问特作如下声明： 1、本次交易涉及的各方当事人向本独立财务顾问提供了出具本独立财务顾 问报告所必需的资料，并且保证所提供的资料真实、准确、完整，不存在任何 ...

股票简称：中毅达 股票代码：600610 股票简称：中毅达 B 股票代码：900906 上市地点：上海证券交易所 贵州中毅达股份有限公司 发行股份购买资产并募集配套资金 暨关联交易报告书（草案）摘要 | 交易对方 | 名称 | | --- | --- | | 发行股份购买资产交易对方 | 中国信达资产管理股份有限公司 | | | 国投矿业投资有限公司 | | | 工银金融资产投资有限公司 | | | 农银金融资产投资有限公司 | | | 贵州省黔晟国有资产经营有限责任公司 | | | 贵州省人民政府国有资产监督管理委员会 | | | 中国建设银行股份有限公司 | | | 建信金融资产投资有限公司 | | | 深圳市前海华建股权投资有限公司 | | | 鑫丰环东股权投资有限公司 | | 募集配套资金认购方 | 不超过 名特定投资者 35 | （修订稿） 独立财务顾问 签署时间：二〇二三年八月 1 贵州中毅达股份有限公司 发行股份购买资产并募集配套资金暨关联交易报告书（草案）摘要 公司声明 本重大资产重组报告书摘要的目的仅为向公众提供有关本次重组的简要情 况，并不包括重大资产重组报告书全文的各部分内容。重大资产重 ...

A 股证券代码：600610 A 股证券简称：中毅达 公告编号：2023-048 B 股证券代码：900906 B 股证券简称：中毅达 B 公司本次发行股份购买资产并募集配套资金暨关联交易事项尚需上交所审 核通过并报中国证监会注册，能否审核通过、完成注册及最终审核通过、完成注 册的时间尚存在不确定性。公司将根据该事项的进展情况及时履行信息披露义 务。公司指定信息披露媒体为《中国证券报》《上海证券报》和上交所网站 （www.sse.com.cn）。有关公司信息均以在上述指定媒体披露的公告为准，敬请 广大投资者注意投资风险。 特此公告。 贵州中毅达股份有限公司董事会 2023 年 8 月 25 日 贵州中毅达股份有限公司（以下简称"公司"）拟以发行股份方式购买瓮福 （集团）有限责任公司 100%股权并募集配套资金（以下简称"本次重组"）。 2023 年 3 月 2 日，公司收到上海证券交易所（以下简称"上交所"）出具 的《关于受理贵州中毅达股份有限公司发行股份购买资产并募集配套资金申请的 通知》（上证上审〔2023〕2 号），上交所依据相关规定对公司报送的发行股份 购买资产并募集配套资金的申请文件进行了核对，认为 ...

A 股证券代码：600610 A 股证券简称：中毅达 公告编号：2023-046 B 股证券代码：900906 B 股证券简称：中毅达 B 贵州中毅达股份有限公司 第八届监事会第二十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贵州中毅达股份有限公司（以下简称"公司"）第八届监事会第二十一次会 议（以下简称"本次会议"）于 2023 年 8 月 25 日以通讯表决的方式召开。会议 应参加表决监事 3 名，亲自出席监事 3 名。 监事会主席夜文彦先生召集和主持了本次会议。本次会议的召开符合有关法 律、法规及《公司章程》的规定。 二、监事会会议审议情况 （一） 审议通过《关于<2023 年半年度报告>及摘要的议案》 经审议，监事会认为：公司《2023 年半年度报告》及摘要的编制、审议符 合相关法律法规及《公司章程》的规定。公司编制的《2023 年半年度报告》及 摘要真实、准确、完整地反映了公司的财务状况和经营成果，不存在任何虚假记 载、误导性陈述或重大遗漏，未发现参与《2023 年半年度报告》编制和审议的 人员 ...

上海市方达律师事务所 关于贵州中毅达股份有限公司 发行股份购买资产并募集配套资金暨关联交易的 补充法律意见书（七） 2023 年 8 月 FANGDA PARTNERS 上海 Shanghai·北京 Beijing·深圳 Shenzhen·广州 Guangzhou 香港 Hong Kong· http://www.fangdalaw.com | 中国上海市石门一路 288 号 | 电子邮件 E-mail: email@fangdalaw.com | | | | --- | --- | --- | --- | | 兴业太古汇香港兴业中心二座 24 楼 | 电 话 | Tel.: | 86-21-2208-1166 | | 邮政编码：200041 | 传 真 | Fax: | 86-21-5298-5599 | 24/F, HKRI Centre Two, HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai 200041, China 上海市方达律师事务所 关于贵州中毅达股份有限公司 发行股份购买资产并募集配套资金暨关联交易的 补充法律意见书（七） 致：贵州中毅达股份有限公司 ...

A 股证券代码：600610 A 股证券简称：中毅达 公告编号：2023-026 B 股证券代码：900906 B 股证券简称：中毅达 B 贵州中毅达股份有限公司 关于参加 2022 年度贵州辖区上市公司业绩说明会暨 投资者集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 17 日（星期三）15:30-17:00 会议召开方式：网络远程方式 投资者可于本公告发出之日起至 2023 年 5 月 15 日，通过微信关注"贵 州资本市场"公众号，发送关键词"提问"即可进入专区提问。公司将在本 次说明会上对投资者普遍关注的问题进行回答。 贵州中毅达股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日于《中 国证券报》《上海证券报》及上海证券交易所网站（www.sse.com.cn）发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、 财务状况，公司将参加在贵州证监局指导下、贵州证券业协会联合深圳市全景网 络 ...

A 股证券代码：600610 A 股证券简称：中毅达 公告编号：2023-026 B 股证券代码：900906 B 股证券简称：中毅达 B 贵州中毅达股份有限公司 关于参加 2022 年度贵州辖区上市公司业绩说明会暨 投资者集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于本公告发出之日起至 2023 年 5 月 15 日，通过微信关注"贵 州资本市场"公众号，发送关键词"提问"即可进入专区提问。公司将在本 次说明会上对投资者普遍关注的问题进行回答。 贵州中毅达股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日于《中 国证券报》《上海证券报》及上海证券交易所网站（www.sse.com.cn）发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、 财务状况，公司将参加在贵州证监局指导下、贵州证券业协会联合深圳市全景网 络有限公司举办的"2022 年度贵州辖区上市公司业绩说明会暨投资者集体接待 日"活动。 一、说明会类型 本次 ...

Financial Performance - The company reported a cumulative undistributed profit balance of -1,995.42 million RMB at the end of 2022, resulting in no profit distribution or capital reserve increase plan for the year[5]. - The company's operating revenue for 2022 was approximately ¥1.366 billion, a decrease of 2.01% compared to ¥1.394 billion in 2021[24]. - Net profit attributable to shareholders was ¥11.116 million in 2022, down 73.46% from ¥41.888 million in 2021[24]. - The net profit after deducting non-recurring gains and losses was ¥9.390 million, reflecting an 83.66% decline from ¥57.457 million in 2021[24]. - The net cash flow from operating activities decreased by 23.28% to ¥58.777 million from ¥76.609 million in 2021[24]. - The company's total assets at the end of 2022 were approximately ¥1.287 billion, a decrease of 5.52% from ¥1.362 billion at the end of 2021[24]. - Basic earnings per share for 2022 were ¥0.0104, down 73.40% from ¥0.0391 in 2021[25]. - The weighted average return on equity decreased to 8.09% in 2022, down 29.69 percentage points from 37.78% in 2021[25]. - The gross margin for polyol products significantly declined due to a drop in product prices, which fell more than the decrease in raw material prices[26]. - The gross profit margin for pentaerythritol products decreased significantly in 2022 due to rising raw material prices and weakened downstream demand[57]. - The company achieved a revenue of CNY 136,600.38 million and a net profit of CNY 1,111.59 million, with a slight decline in main business revenue by 1.16% compared to the previous year[39]. Corporate Governance - The company held one annual general meeting and three extraordinary general meetings during the reporting period, passing 15 resolutions to ensure shareholder rights are protected[140]. - The board of directors consists of seven members, including three independent directors, and has convened nine meetings, passing 35 resolutions, ensuring compliance with legal requirements[140]. - The supervisory board held eight meetings, passing 23 resolutions, maintaining effective oversight of the company's operations and financial status[141]. - The company disclosed 68 announcements and 79 other disclosure documents during the reporting period, ensuring transparency and timely information for investors[141]. - There were no instances of related party transactions harming the interests of the company or its shareholders during the reporting period[142]. - The company has implemented measures to maintain independence from its controlling shareholder, ensuring no interference in decision-making processes[142]. - The company is focused on compliance and transparency in its shareholder meetings, adhering to legal and regulatory requirements[145]. - The company’s independent directors have diverse backgrounds, including finance and law, enhancing governance[148]. - The company is committed to maintaining rigorous standards in its corporate governance practices[145]. Risk Management - The company has detailed potential risks in its report, particularly in the section discussing future development and risks[9]. - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements in its report[6]. - The company has faced risks related to safety and environmental compliance due to the nature of its chemical production processes[131]. - The company has not experienced goodwill impairment as of the end of 2022, but future industry conditions could pose risks[134]. - The company is undergoing a major asset restructuring to acquire 100% of Wengfu Group, which will significantly reduce its debt-to-asset ratio and eliminate liquidity risks on a consolidated basis[136]. Research and Development - The company has applied for 5 new invention patents and received 3 authorized invention patents during the reporting period, enhancing its innovation capabilities[40]. - The company has developed a total of 46 patents, including 9 invention patents, with a core patent for the production method of pentaerythritol[59]. - The company has established a research and development model in collaboration with renowned universities, enhancing its R&D capabilities and technological level[59]. - The company has established a complete new product R&D process covering all stages from project initiation to industrial production[104]. - The company has a total of 123 R&D personnel, including 7 core R&D staff, focusing on enhancing product competitiveness and extending the industrial chain[106]. Environmental Compliance - The company has implemented a three-year action plan for hazardous waste safety management, resulting in no environmental pollution incidents during the reporting period[41]. - The company has established a comprehensive environmental management system, achieving compliance with the pollution discharge permit management regulations[41]. - The company has maintained compliance with environmental discharge standards, with no exceedances reported for key pollutants during the reporting period[182]. - The company has successfully operated multiple pollution control facilities, including a wastewater treatment plant and a waste incineration facility, since their respective commissioning dates[184]. - The company has focused on energy-saving and emission-reduction technologies, optimizing production processes to lower energy consumption[190]. Strategic Initiatives - The company plans to acquire 100% equity of Wengfu Group for a valuation of CNY 1,132,453.93 million, issuing shares at CNY 5.10 per share[33]. - The acquisition will increase the company's main business to include phosphate mining and production, significantly enhancing asset scale and profitability[34]. - The company has applied for administrative approval for the asset acquisition, which is currently under review by the Shanghai Stock Exchange[37]. - The company has filed for a fundraising of up to CNY 166,000 million to support the acquisition and related projects[33]. - The company aims to enhance its competitive advantage in core products like pentaerythritol and trimethylolpropane, while expanding production capacity and optimizing product structure[125]. Operational Efficiency - The company has maintained stable production with an increase in the output of polyol series products, while optimizing product structure based on market demand[39]. - The company plans to optimize production processes and strengthen equipment management to enhance production efficiency[74]. - The company has implemented advanced non-patented technologies in the production of food-grade alcohol, achieving high fermentation conversion rates[107]. - The company has a strategic advantage in procurement, particularly for corn, which is sourced through various channels to optimize costs[53]. - The company is located in a region with favorable logistics and low energy costs, enhancing its competitive edge in production[60]. Financial Management - The company has a debt-to-asset ratio of 88.89% as of December 31, 2022, indicating a high level of financial leverage[135]. - The financing activities resulted in a net cash outflow of RMB 55,055,850.94, a significant increase compared to the previous year[65]. - The company's total cost of raw materials for the multi-functional alcohol segment was CNY 442,251,281.78, accounting for 36.96% of total costs, an increase of 3.86% compared to the previous year[76]. - The company's management expenses decreased by 27.88% to CNY 63,274,000, mainly due to a reduction in employee salary provisions and lower restructuring service fees[82]. - The company has a cash dividend policy in place, which is subject to adjustments based on performance[171]. Employee Management - The company reported a total of 800 employees, with 643 in production, 21 in sales, 61 in technical roles, 12 in finance, 51 in administration, and 12 in supply[167]. - The company has established a performance evaluation system linking individual income directly to operational performance for all employees[168]. - The company has implemented effective training programs to enhance employees' capabilities and promote overall development[169]. - The total remuneration for all directors, supervisors, and senior management personnel for the reporting period amounted to 5.3715 million yuan[155]. Shareholder Relations - The company is committed to providing accurate and complete information regarding the major asset restructuring process, ensuring compliance with relevant laws and regulations[197]. - The company will ensure that any information disclosed during the major asset restructuring is truthful and complete, accepting legal responsibility for any misleading statements[197]. - The company has assured that all disclosures related to the major asset restructuring will be made in accordance with the requirements of the China Securities Regulatory Commission and the stock exchange[197].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 325,861,894.61, representing a decrease of 5.03% compared to the same period last year [5]. - The net profit attributable to shareholders was a loss of CNY 11,743,230.18, a decline of 165.27% year-on-year [5]. - The basic and diluted earnings per share were both CNY -0.0110, reflecting a decrease of 165.48% compared to the previous year [6]. - Total revenue for Q1 2023 was ¥325,861,894.61, a decrease of 5.5% compared to ¥343,129,262.68 in Q1 2022 [21]. - Net profit for Q1 2023 was a loss of ¥11,743,230.18, compared to a profit of ¥17,990,460.87 in Q1 2022, representing a significant decline [22]. - Basic and diluted earnings per share for Q1 2023 were both -¥0.0110, down from ¥0.0168 in Q1 2022 [23]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 3,044,980.72, down 97.52% from the same period last year [5]. - Cash flow from operating activities generated a net inflow of ¥3,044,980.72, a decrease of 97.5% from ¥122,822,521.70 in Q1 2022 [26]. - Cash received from sales of goods and services was ¥302,005,576.93, down 11.7% from ¥342,014,700.60 in the previous year [25]. - Cash outflow for operating activities totaled ¥303,854,206.08, an increase of 38.3% compared to ¥219,623,636.78 in Q1 2022 [26]. - The total cash and cash equivalents at the end of the period decreased to $44.12 million from $182.64 million year-over-year [27]. - The cash and cash equivalents net increase for the period was -$21.39 million, compared to an increase of $76.61 million in the same period last year [27]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,239,864,169.72, down 3.65% from the end of the previous year [6]. - Current assets totaled CNY 436,563,636.86, down from CNY 467,524,791.35, indicating a decrease of about 6.62% [19]. - Cash and cash equivalents were CNY 52,587,347.56, compared to CNY 74,090,564.06 at the end of 2022, representing a decline of approximately 29.05% [18]. - Accounts receivable increased to CNY 28,786,819.29 from CNY 19,968,098.66, marking a rise of about 44.1% [18]. - Total liabilities decreased to CNY 1,108,434,052.43 from CNY 1,143,852,286.70, a reduction of approximately 3.09% [20]. - The company's equity attributable to shareholders was CNY 131,430,117.29, down from CNY 142,926,240.98, reflecting a decrease of about 8.06% [20]. Operational Challenges - The company adjusted its sales strategy for polyol products due to weakened demand in downstream industries [10]. - The decline in net profit was attributed to the drop in prices of main products, including trimethylolpropane and pentaerythritol, which exceeded the decrease in raw material costs [10]. - The company reported a significant increase in cash payments for bulk raw materials compared to the previous period [11]. - The company plans to focus on cost control and efficiency improvements in response to the current financial challenges [21]. Subsidiary Management - The company has completed the disposal of two subsidiaries, with no actual gains realized from these disposals as of Q1 2023 [16]. - The company is actively monitoring the asset disposal progress of its subsidiary, 盛云投资, to protect the interests of the company and minority shareholders [16]. - The company continues to pursue bankruptcy proceedings for its subsidiary, 厦门中毅达, and is handling cases related to other subsidiaries [16].